Top

BMC Cancer

Published in:

Open Access 01-12-2023 | Endometrial Cancer | Research

Development and validation of a nomogram for predicting overall survival in patients with early-onset endometrial cancer

Authors: Meng Zhang, Ruiping Li, Jiaxi Zhang, Yunyun Wang, Yunlu Wang, Yuzhen Guo

Published in: BMC Cancer | Issue 1/2023

Abstract

Background

This study aimed to investigate the differences in the clinicopathological characteristics of younger and older patients with endometrial cancer (EC) and develop a nomogram to assess the prognosis of early onset EC in terms of overall survival.

Methods

Patients diagnosed with EC from the Surveillance, Epidemiology, and End Results (SEER) database between 2004 and 2015 were selected. Clinicopathological characteristics were compared between younger and older patients, and survival analysis was performed for both groups. Prognostic factors affecting overall survival in young patients with EC were identified using Cox regression. A nomogram was created and internal validation was performed using the consistency index, decision curve analysis, receiver operating characteristic curves, and calibration curves. External validation used data from 70 patients with early onset EC. Finally, Kaplan-Meier curves were plotted to compare survival outcomes across the risk subgroups.

Results

A total of 1042 young patients and 12,991 older patients were included in this study. Younger patients were divided into training (732) and validation (310) cohorts in a 7:3 ratio. Cox regression analysis identified age, tumorsize, grade, FIGO stage(International Federation of Gynecology and Obstetrics) and surgery as independent risk factors for overall survival, and a nomogram was constructed based on these factors. Internal and external validations demonstrated the good predictive power of the nomogram. In particular, the C-index for the overall survival nomogram was 0.832 [95% confidence interval (0.797–0.844)] in the training cohort and 0.839 (0.810–0.868) in the internal validation cohort. The differences in the Kaplan-Meier curves between the different risk subgroups were statistically significant.

Conclusions

In this study, a nomogram for predicting overall survival of patients with early onset endometrial cancer based on the SEER database was developed to help assess the prognosis of patients and guide clinical treatment.

Available only for authorised users

Lucchini SM, Esteban A, Nigra MA, et al. Updates on Conservative management of endometrial cancer in patients younger than 45 years[J]. Gynecol Oncol. 2021;161(3):802–9.CrossRefPubMed

Li J, Zhu Q, Yang B, et al. Risk factors for ovarian involvement in young and premenopausal endometrioid endometrial cancer patients[J]. Eur J Obstet Gynecol Reprod Biol. 2018;222:151–4.CrossRefPubMed

Smrz SA, Calo C, Fisher JL, et al. An ecological evaluation of the increasing incidence of endometrial cancer and the obesity epidemic[J]. Am J Obstet Gynecol. 2021;224(5):501–6.CrossRef

Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021[J]. CA Cancer J Clin. 2021;71(1):7–33.CrossRefPubMed

Mutlu L, Manavella DD, Gullo G et al. Endometrial Cancer in Reproductive Age: Fertility-Sparing Approach and Reproductive Outcomes[J]. Cancers (Basel), 2022,14(21).

Zabuliene L, Kaceniene A, Steponaviciene L et al. Risk of Endometrial Cancer in women with Diabetes: a Population-based retrospective cohort Study[J]. J Clin Med, 2021,10(16).

Ren F, Wang S, Li F, et al. Clinical nomograms for Predicting the overall survival and Cancer-specific survival of patients with ovarian carcinosarcoma patients after primary Surgery[J]. J Cancer. 2021;12(23):7223–36.CrossRefPubMedPubMedCentral

Choi J, Holowatyj AN, Du M, et al. Distinct genomic landscapes in early-onset and late-onset endometrial Cancer[J]. JCO Precis Oncol. 2022;6:e2100401.CrossRefPubMedPubMedCentral

Nelson AL, Vasquez L, Tabatabai R, et al. The yield of endometrial aspiration in women with various risk factors and bleeding abnormalities[J]. Contracept Reprod Med. 2016;1:9.CrossRefPubMedPubMedCentral

10.

Li X, Fan Y, Dong Y, et al. Development and validation of Nomograms Predicting the overall and the Cancer-Specific Survival in Endometrial Cancer Patients[J]. Front Med (Lausanne). 2020;7:614629.CrossRefPubMed

11.

Yang J, Li Y, Liu Q, et al. Brief introduction of medical database and data mining technology in big data era[J]. J Evid Based Med. 2020;13(1):57–69.CrossRefPubMedPubMedCentral

12.

Wu WT, Li YJ, Feng AZ, et al. Data mining in clinical big data: the frequently used databases, steps, and methodological models[J]. Mil Med Res. 2021;8(1):44.PubMedPubMedCentral

13.

Tarney CM, Tian C, Wang G, et al. Impact of age at diagnosis on racial disparities in endometrial cancer patients[J]. Gynecol Oncol. 2018;149(1):12–21.CrossRefPubMed

14.

Parthasarathy S, Shen Z, Carrillo-Salinas FJ, et al. Aging modifies endometrial dendritic cell function and unconventional double negative T cells in the human genital mucosa[J]. Immun Ageing. 2023;20(1):34.CrossRefPubMedPubMedCentral

15.

Chung YS, Woo HY, Lee JY, et al. Mismatch repair status influences response to fertility-sparing treatment of endometrial cancer[J]. Am J Obstet Gynecol. 2021;224(4):370–1.CrossRef

16.

Baskovic M, Lichtensztajn DY, Nguyen T, et al. Racial disparities in outcomes for high-grade Uterine cancer: a California cancer registry study[J]. Cancer Med. 2018;7(9):4485–95.CrossRefPubMedPubMedCentral

17.

Clarke MA, Long BJ, Sherman ME, et al. Risk assessment of endometrial cancer and endometrial intraepithelial neoplasia in women with abnormal bleeding and implications for clinical management algorithms[J]. Am J Obstet Gynecol. 2020;223(4):541–9.CrossRef

18.

Bendifallah S, Ilenko A, Darai E. High risk endometrial cancer: clues towards a revision of the therapeutic paradigm[J]. J Gynecol Obstet Hum Reprod. 2019;48(10):863–71.CrossRefPubMed

19.

Murali R, Davidson B, Fadare O et al. High-grade Endometrial Carcinomas: Morphologic and Immunohistochemical Features, Diagnostic Challenges and Recommendations[J]. Int J Gynecol Pathol, 2019,38 Suppl 1(Iss 1 Suppl 1):S40-S63.

20.

Pellerin GP, Finan MA. Endometrial cancer in women 45 years of age or younger: a clinicopathological analysis[J]. Am J Obstet Gynecol. 2005;193(5):1640–4.CrossRefPubMed

21.

Fu HC, Chen JR, Chen MY, et al. Treatment outcomes of patients with stage II pure endometrioid-type endometrial cancer: a Taiwanese Gynecologic Oncology Group (TGOG-2006) retrospective cohort study[J]. J Gynecol Oncol. 2018;29(5):e76.CrossRefPubMedPubMedCentral

22.

Haley L, Burmeister C, Buekers T, et al. Is older Age a real adverse prognostic factor in Women with Early-Stage Endometrial Carcinoma? A matched Analysis[J]. Int J Gynecol Cancer. 2017;27(3):479–85.CrossRefPubMed

23.

Dong J, Dai Q, Zhang F. The effect of marital status on endometrial cancer-related diagnosis and prognosis: a Surveillance Epidemiology and End results database analysis[J]. Future Oncol. 2019;15(34):3963–76.CrossRefPubMed

24.

Yuan R, Zhang C, Li Q, et al. The impact of marital status on stage at diagnosis and survival of female patients with breast and gynecologic cancers: a meta-analysis[J]. Gynecol Oncol. 2021;162(3):778–87.CrossRefPubMed

25.

Chen ZH, Yang KB, Zhang YZ, et al. Assessment of Modifiable Factors for the Association of Marital Status with Cancer-Specific Survival[J]. JAMA Netw Open. 2021;4(5):e2111813.CrossRefPubMedPubMedCentral

26.

Lowery WJ, Stany MP, Phippen NT, et al. Survival advantage of marriage in Uterine cancer patients contrasts poor outcome for widows: a Surveillance, Epidemiology and End results study[J]. Gynecol Oncol. 2015;136(2):328–35.CrossRefPubMed

27.

Zhu L, Sun X, Bai W. Nomograms for Predicting Cancer-Specific and overall survival among patients with endometrial carcinoma: a SEER based Study[J]. Front Oncol. 2020;10:269.CrossRefPubMedPubMedCentral

28.

Liang S, Zhang Y. Clinical pathological characteristics and survival of high-grade endometrioid carcinoma[J]. J Obstet Gynaecol Res. 2021;47(10):3644–51.CrossRefPubMed

29.

Evans-Metcalf ER, Brooks SE, Reale FR, et al. Profile of women 45 years of age and younger with endometrial cancer[J]. Obstet Gynecol. 1998;91(3):349–54.CrossRefPubMed

30.

Huo X, Wang SA, Lymph Node. Count-based AJCC staging System facilitates a more accurate prediction of the prognosis of patients with endometrial Cancer[J]. Front Oncol. 2021;11:641962.CrossRefPubMedPubMedCentral

31.

Rees M, Angioli R, Coleman RL, et al. European menopause and Andropause Society (EMAS) and International Gynecologic Cancer Society (IGCS) position statement on managing the menopause after gynecological cancer: focus on menopausal symptoms and osteoporosis[J]. Maturitas. 2020;134:56–61.CrossRefPubMed

32.

van den Heerik A, Horeweg N, de Boer SM, et al. Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy[J]. Int J Gynecol Cancer. 2021;31(4):594–604.CrossRefPubMed

33.

Herrera CE, Humann J, Torrejon R, et al. Chances of pregnancy and live birth among women undergoing Conservative management of early-stage endometrial cancer: a systematic review and meta-analysis[J]. Hum Reprod Update. 2022;28(2):282–95.CrossRef

34.

Gallo A, Catena U, Saccone G et al. Conservative Surgery in Endometrial Cancer[J]. J Clin Med, 2021,11(1).

35.

Straubhar AM, Parsons MW, Francis S, et al. Refusal of Surgery and survival outcomes in endometrial cancer[J]. Int J Gynecol Cancer. 2021;31(9):1236–41.CrossRefPubMed

Title: Development and validation of a nomogram for predicting overall survival in patients with early-onset endometrial cancer
Authors: Meng Zhang
Ruiping Li
Jiaxi Zhang
Yunyun Wang
Yunlu Wang
Yuzhen Guo
Publication date: 01-12-2023
Publisher: BioMed Central
Keywords: Endometrial Cancer
Endometrial Cancer
Published in: BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-023-11682-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2023

Pan-cancer analysis of TASL: a novel immune infiltration-related biomarker for tumor prognosis and immunotherapy response prediction

Primary head and neck cancer cell cultures are susceptible to proliferation of Epstein-Barr virus infected lymphocytes

A differential diagnosis between uterine leiomyoma and leiomyosarcoma using transcriptome analysis

Cancer incidence and mortality in Brunei Darussalam, 2011 to 2020

Protocol for the 2ND-STEP study, Japan Clinical Oncology Group study JCOG1802: a randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib

Sintilimab plus nab-paclitaxel as second-line treatment for advanced biliary tract cancer: study protocol for an investigator-initiated phase 2 trial (NapaSinti trial)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer